Cargando…
ADVANCES IN CLINICAL CHEMISTRY. 114
Advances in Clinical Chemistry, Volume 112 highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Heterogeneity in Major Depressive Disorder: The need for Biomarker-based and Personalized Treatments, Advances in exosome ana...
| Clasificación: | Libro Electrónico |
|---|---|
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
[S.l.] :
ELSEVIER ACADEMIC PRESS,
2023.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000M 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_on1360515894 | ||
| 003 | OCoLC | ||
| 005 | 20231120010722.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 230311s2023 xx o 0|| 0 eng d | ||
| 040 | |a YDX |b eng |c YDX |d SFB |d YDX |d OPELS |d OCLCF |d OCLCO | ||
| 020 | |a 9780443192876 |q (electronic bk.) | ||
| 020 | |a 0443192871 |q (electronic bk.) | ||
| 020 | |a 9780443192883 |q (electronic bk.) | ||
| 020 | |a 044319288X |q (electronic bk.) | ||
| 035 | |a (OCoLC)1360515894 | ||
| 050 | 4 | |a RB40 |b .A383 2023 | |
| 082 | 0 | 4 | |a 616.0756 |
| 245 | 0 | 0 | |a ADVANCES IN CLINICAL CHEMISTRY. |n 114 |h [electronic resource]. |
| 260 | |a [S.l.] : |b ELSEVIER ACADEMIC PRESS, |c 2023. | ||
| 300 | |a 1 online resource | ||
| 505 | 0 | |a Intro -- Advances in Clinical Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Biosensors for saliva biomarkers -- 1. Introduction -- 2. Saliva as a noninvasive diagnostic fluid -- 3. Biomarkers in human saliva -- 4. Biosensors for saliva biomarkers -- 4.1. Bacterial and viral biomarkers -- 4.2. Cancer biomarkers -- 4.3. Cardiac biomarkers -- 4.4. Protein and other biomarkers -- 4.5. Drugs and toxic compound biomarkers -- 5. Conclusions and future perspectives -- References -- Chapter Two: Biochemistry and pathophysiology of the Transient Potential Receptor Vanilloid 6 (TRPV6) calcium channel -- 1. Introduction -- 2. The TRPV6 gene -- 3. Physiology of TRPV6 -- 3.1. Tissue expression -- 3.2. Regulation of TRPV6 activity -- 3.3. Channel properties -- 4. Analytical methods -- 4.1. Measurement of intracellular Ca -- 4.2. Measurement of ion currents -- 4.3. The 3-dimensional structure of TRPV6 -- 4.3.1. X-ray crystallography -- 4.3.2. Single particle cryogenic-electron microscopy (cryo-EM) -- 4.3.3. Nuclear magnetic resonance (NMR) spectroscopy -- 5. Molecular structure and mechanics of TRPV6 -- 5.1. Structure -- 5.2. Inactivation of the TRPV6 channel by Ca-bound calmodulin -- 5.2.1. CaM interaction with TRPV6 -- 5.2.2. Proposed mechanism of channel closure -- 5.3. Proteins associated with TRPV6 -- 6. Establishing the roles of TRPV6 in vivo -- 7. TRPV6 deficiency due to gene mutations -- 7.1. Inherited deficiencies in humans -- 7.1.1. Transient hyperparathyroidism of the newborn (OMIM 618188) -- 7.1.2. Non-alcoholic chronic pancreatitis (CP) -- 7.1.3. Calcium kidney stone formation -- 7.2. TRPV6 deficiency in zebra fish -- 7.3. TRPV6 deficiency in mouse models -- 8. TRPV6 in intestinal Ca absorption -- 8.1. Active transcellular absorption -- 8.2. Paracellular absorption -- 8.2.1. Intercellular junctions. | |
| 505 | 8 | |a 8.2.2. A possible role for TRPV6 in intestinal paracellular Ca absorption? -- 8.3. Regulation of intestinal Ca transport by 1,25 (OH)2D3 -- 9. TRPV6 deficiency in pregnancy -- 9.1. TRPV6 in the normal placenta -- 9.2. Effects of TRPV6 deficiency on the placenta -- 9.3. TRPV6 in pre-eclamptic toxemia -- 9.4. Bone abnormalities in fetuses and neonates with TRPV6 deficiency -- 10. Male infertility in TRPV6 deficiency -- 11. Alopecia in TRPV6-deficient mice -- 12. TRPV6 in cancers -- 12.1. Overview -- 12.1.1. TRPV6 in tumor growth and metastasis -- 12.1.2. TRPV6 in epithelial-mesenchymal transition (EMT) -- 12.2. TRPV6 in breast cancer -- 12.3. TRPV6 in prostate cancer -- 12.4. TRPV6 in colon cancer -- 13. Concluding remarks -- References -- Chapter Three: Protein glycation in diabetes mellitus -- 1. Introduction -- 2. Diabetes mellitus -- 3. Protein glycation -- 4. Glucose and Hyperglycemia -- 5. Glycated hemoglobin -- 5.1. History and clinical significance of HbA1c -- 5.2. HbA1c Standardization -- 5.3. Limitations of HbA1c -- 6. Glycated albumin -- 6.1. GA. Background -- 6.2. GA as an indicator of hyperglycemia -- 6.3. GA as a predictor of diabetes complications -- 6.4. Limitations of GA -- 7. Other glycated proteins -- 8. Application of proteomics workflows for glycated proteins -- 9. Conclusion -- References -- Chapter Four: Biomarkers of oxidative stress and reproductive complications -- 1. Introduction -- 2. Free radicals in biology and health: ROS and RNS -- 3. Biomarkers measuring evidence of the direct chemical impact of free radicals in biological systems -- 3.1. Lipid oxidation products -- 3.1.1. Initial intermediates -- 3.1.2. Lipid hydroperoxides -- 3.1.3. Isoprostanes (IsoPs) -- 3.1.4. Isolevuglandins (IsoLGs) -- 3.1.5. Isofurans (IsoFs) -- 3.1.6. F4-neuroprostanes (F4-NPs) and neurofurans (NFs) -- 3.1.7. Malondialdehyde. | |
| 505 | 8 | |a 3.1.8. 4-hydroxy-2-trans-nonenal (4-HNE) -- 3.2. Protein oxidation products -- 3.2.1. Carbonyl groups -- 3.2.2. Advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs) -- 3.2.3. Advanced oxidation protein products (AOPP) -- 3.2.4. Ischemia-modified albumin (IMA) -- 3.2.5. Oxidized low-density lipoproteins (oxLDL) -- 3.2.6. Oxidized sulfur-containing amino acids -- 3.2.7. 3-Nitrotyrosine (3-NT) -- 3.3. Products of the oxidation of nucleic acids -- 3.4. Oxidation of uric acid: Allantoin -- 3.5. Total antioxidant capacity -- 3.6. Oxidation-reduction potential (ORP) -- 3.7. Novel biomarkers of oxidative stress -- 3.7.1. Osmotic fragility of red blood cells -- 3.7.2. Exosomes -- 3.7.3. Heart rate variability and oxidative stress severity -- 3.7.4. Reactive oxygen metabolites (ROM) and biological antioxidant potential (BAP) -- 4. Oxidative stress and healthy pregnancy -- 4.1. Oxidative stress and embryonic development -- 4.2. Role of oxidative stress during early embryogenesis -- 4.3. Placental oxidative stress -- 5. Oxidative stress in reproductive complications -- 5.1. Male infertility -- 5.2. Female infertility -- 5.3. Endometriosis -- 5.4. Polycystic ovarian syndrome -- 5.5. Ovarian torsion -- 5.6. Assisted reproductive techniques -- 5.7. Preeclampsia -- 5.8. Intrauterine growth restriction -- 5.9. Miscarriages -- 5.10. Gestational diabetes mellitus -- 5.11. Premature rupture of membranes -- 6. Summary and future perspectives -- Acknowledgments -- References -- Chapter Five: Cortisol: Analytical and clinical determinants -- 1. Cortisol biochemistry and metabolism -- 2. Evolution of cortisol assays -- 3. Cortisol measurement in serum -- 3.1. Pre-analytic considerations -- 3.2. Analytical considerations -- 3.3. Free serum cortisol -- 4. Cortisol measurement in urine -- 4.1. Pre-analytic considerations. | |
| 505 | 8 | |a 4.2. Analytical considerations -- 5. Cortisol measurement in saliva -- 5.1. Pre-analytic considerations -- 5.2. Analytic considerations -- 6. Cortisol measurement in hair -- 6.1. Pre-analytic considerations -- 6.2. Analytic considerations -- 7. Clinical value of cortisol measurement -- 8. Summary -- References -- Chapter Six: Hemophilia A: Emicizumab monitoring and impact on coagulation testing -- 1. Introduction -- 2. Emicizumab -- 2.1. Development of emicizumab -- 2.2. Mechanism of action -- 3. Clinical studies of emicizumab -- 3.1. HAVEN studies -- 3.2. Other studies -- 3.3. Summary of clinical studies -- 4. Laboratory testing -- 4.1. Effect of emicizumab on clinical laboratory testing -- 4.2. APTT, FVIII and FVIII inhibitors testing -- 4.3. Effect of emicizumab on the measurement of APTT, FVIII and FVIII inhibitors -- 4.4. Measurement of FVIII and FVIII inhibitors in the presence of emicizumab -- 4.5. Effect of emicizumab on other coagulation laboratory assays -- 4.6. Monitoring plasma emicizumab levels -- 4.7. Measurement of anti-drug antibodies -- 4.8. Global testing -- 4.9. General principle of VEM -- 4.10. General principle of TGA -- 4.11. General principle of CWA -- 4.12. Performance issues and limitations of VEM, TGA, and CWA -- 4.13. VEM, TGA, and/or CWA monitoring of emicizumab therapy -- 5. Guidelines for monitoring emicizumab in the clinical laboratory -- 6. The future -- 7. Conclusion -- References -- Index. | |
| 520 | |a Advances in Clinical Chemistry, Volume 112 highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Heterogeneity in Major Depressive Disorder: The need for Biomarker-based and Personalized Treatments, Advances in exosome analysis, Translational Proteomics and Phosphoproteomics: Tissue to Extracellular Vesicles, Immune Checkpoint Therapy, Tumor Immunology, and Biomarkers in Non-Small-Cell Lung Cancer, Advances in Congestive Heart Failure Biomarkers, Fluid biomarkers in Alzheimer's disease, and more. Provides the most up-to-date technologies in clinical chemistry and clinical laboratory science ; Authored by world renowned clinical laboratory scientists, physicians and research scientists ; Presents the international benchmark for novel analytical approaches in the clinical laboratory. | ||
| 650 | 0 | |a Clinical chemistry. | |
| 650 | 2 | |a Chemistry, Clinical |0 (DNLM)D002624 | |
| 650 | 6 | |a Chimie clinique. |0 (CaQQLa)201-0016714 | |
| 650 | 7 | |a Clinical chemistry |2 fast |0 (OCoLC)fst00864330 | |
| 776 | 0 | 8 | |i Print version: |z 044319288X |z 9780443192883 |w (OCoLC)1336987179 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/00652423/114 |z Texto completo |